Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 10, 2026

Corebridge signals $2.55B individual retirement base spread income outlook for 2026 while accelerating digital investments

View original at seekingalpha.com
Corebridge signals $2.55B individual retirement base spread income outlook for 2026 while accelerating digital investments Earnings Call Insights: Corebridge Financial (CRBG) Q4 2025 MANAGEMENT VIEW * Marc Costantini, President, CEO & Director, recognized outgoing CEO Kevin Hogan and outlined his vision: "Corebridge ha…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • It's too early to tell what the take-up rate has given us, a couple of weeks in, but we feel quite comfortable that we've met all of our usual approach to risk manage the portfolio.

    80% confidence
  • That business, by its nature, is lumpy...but we feel we have a value proposition that's differentiated in the market, and we continue to be quite optimistic about its future.

    80% confidence
  • We expect to grow our total sources of income for the year on the strength of our favorable demographic trends, a competitive and diverse product suite and industry-leading distribution.

    80% confidence
  • Corebridge had a strong year in 2025. Earnings per share were up 4% year-over-year. Return on average equity was up 20 basis points and capital returned to our shareholders was up 13%.

    80% confidence
  • Identified a $30 billion opportunity from expanding Wealth Management through IRA rollovers, enhancing adviser force, and upgrading digital capabilities

    80% confidence
  • Our adjusted ROE was 12.5%, an increase of 140 basis points from the fourth quarter of 2024.

    80% confidence
  • We expect to meet our key financial targets for adjusted ROE, capital return and run rate EPS growth, though at the lower end of our targeted range of 10% to 15%.

    80% confidence
  • As we turn to 2027, I would look at 2027 guidance to be in the upper half of our guidance as opposed to the lower half in 2026.

    80% confidence
  • Our legacy liabilities comprised approximately 1% of the balance sheet.

    80% confidence
  • Operating expenses expected to grow approximately 4% to 5% or $60 million in operating GOE before the full benefits of these strategic investments begin to be realized.

    80% confidence
  • We grew Institutional Markets sales by 24%, overall, led by pension risk transfers and guaranteed investment contracts to drive both current and future earnings growth...In 2025, Corebridge executed the industry's largest variable annuity reinsurance transaction to date.

    80% confidence
  • We reported adjusted pretax operating income of $760 million or operating EPS of $1.22, representing a 15% year-over-year increase.

    80% confidence
  • we feel comfortable with the risk return profile of our business.

    80% confidence
  • We were able, over the course, to adjust the investment allocation, which gave us the flexibility to reduce these macro hedges, and that's what kind of reduced our sensitivity.

    80% confidence
  • The business is in transition from spread business to fee business and that takes some time. We think there's another 12 to 24 months in that transition while we hit the trough there in terms of overall revenue, and then we'll start to increase.

    80% confidence
  • We estimate that overall base spread income for the Individual Retirement business will be in the ZIP code of $2.55 billion for 2026.

    80% confidence
  • Sensitivity to short-term interest rate movements is now down nearly 75% since mid-2024. An additional 25 basis points reduction in SOFR will impact operating earnings by $20 million to $25 million on a go-forward basis.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Corebridge signals $2.55B individual retirement base spread income outlook for 2026 while accelerating digital investments — Source | Via News | ViaNews EU